Want to see ZVSA full AI Analyst Report?
Top Page
ZyVersa Therapeutics
(OTC:ZVSA)
Select Model
Select Model
Rating:39Underperform
Price Target:
$0.11
▲(12.00% Upside)
Action:Reiterated
Date:08/05/26
The score is primarily driven by very weak financial performance (no revenue, large losses, severe cash burn, and deeply negative equity with rising debt), which dominates the risk profile. Technicals also lean bearish with the price below key moving averages and a negative MACD. Corporate events add additional concern due to the move to OTC Pink and the need for strategic alternatives and cost reductions.
Positive Factors
Targeted Clinical Pipeline
ZyVersa’s focus on kidney and metabolic disease therapeutics creates durable strategic focus in areas with chronic unmet needs. A concentrated pipeline targeting inflammatory and fibrotic drivers can produce high-value assets or licensing opportunities if clinical progress continues, preserving strategic optionality.
Negative Factors
No Revenue / Pre-commercial
Zero revenue over multiple years confirms ZyVersa is pre-commercial with no sales-based cash inflows. Sustained absence of top-line revenues means long-term viability depends on external financing or asset monetization, increasing structural dilution and execution risk over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted Clinical Pipeline
ZyVersa’s focus on kidney and metabolic disease therapeutics creates durable strategic focus in areas with chronic unmet needs. A concentrated pipeline targeting inflammatory and fibrotic drivers can produce high-value assets or licensing opportunities if clinical progress continues, preserving strategic optionality.
Read all positive factors
ZyVersa Therapeutics (ZVSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$850.07K
Dividend YieldN/A
Average Volume (3M)51.59K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth57.26%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.32
Shares Outstanding8,095,921
10 Day Avg. Volume65,792
30 Day Avg. Volume51,592
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-156.26
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
ZyVersa Therapeutics Business Overview & Revenue Model
Company Description
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a ch...
How the Company Makes Money
null...
ZyVersa Therapeutics Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
5
Very Negative
Cash Flow
6
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -6.93K | -10.40K | -10.40K | -10.40K |
| EBITDA | -24.69M | -25.29M | -9.14B | -107.74M | -14.43M | -7.25M |
| Net Income | -24.49M | -24.95M | -9.41B | -98.30M | -14.05M | -8.08M |
Balance Sheet | ||||||
| Total Assets | 742.22M | 347.90M | 20.60M | 22.11M | 118.51M | 1.13M |
| Cash, Cash Equivalents and Short-Term Investments | 302.66M | 101.78M | 1.53M | 3.14M | 5.90M | 328.58K |
| Total Debt | 1.20B | 0.00 | 0.00 | 8.66K | 108.76K | 9.15M |
| Total Liabilities | 14.87B | 12.73B | 12.08M | 11.04M | 18.51M | 13.63M |
| Stockholders Equity | -14.12M | -12.39B | 8.52M | 11.07M | 99.99M | -12.50M |
Cash Flow | ||||||
| Free Cash Flow | -2.62B | -5.11M | -7.56M | -8.72M | -1.49M | -5.08M |
| Operating Cash Flow | -2.62B | -5.11M | -7.56M | -8.72M | -4.89M | -5.08M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 2.83B | 3.69M | 5.95M | 5.96M | 1.87M | 5.23M |
ZyVersa Therapeutics Risk Analysis
ZyVersa Therapeutics disclosed 86 risk factors in its most recent earnings report. ZyVersa Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Following a reverse stock split, the resulting market price of our Common Stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our Common Stock may not improve. Q4, 2023
2.
Our reverse stock split may decrease the liquidity of the shares of our Common Stock. Q4, 2023
3.
Unless our Common Stock continues to be listed on a national securities exchange it will become subject to the so-called "penny stock" rules that impose restrictive sales practice requirements. Q4, 2023
ZyVersa Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
ZVSA
ZyVersa Therapeutics
0.10
-0.02
-17.50%
SCNI
Scinai Immunotherapeutics
2.50
-12.80
-83.66%
ADTX
Aditxt
0.04
-25,384.28
-100.00%
CERO
CERo Therapeutics Holdings
0.01
-7.39
-99.84%
PBM
Psyence Biomedical
4.34
-13.22
-75.29%
CDT
CDT Equity
1.68
-2,658.32
-99.94%
ZyVersa Therapeutics Corporate Events
Delistings and Listing Changes
ZyVersa Therapeutics Transitions to OTC Pink Market
Negative
Jul 17, 2026
Effective July 16, 2026, ZyVersa Therapeutics, Inc. ceased trading on the OTCQB Venture Market and began trading on the OTC Pink Limited Market. The move to the OTC Pink tier represents a change in the company’s trading status that may affec...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
ZyVersa Therapeutics Pursues Strategic Alternatives, Cuts Costs
Negative
Jul 10, 2026
ZyVersa Therapeutics’ board and management have begun implementing and evaluating cost-cutting measures to preserve cash while the company seeks to raise capital. Chief Executive Officer Stephen Glover and Chief Financial Officer Peter Wolfe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.